Business UpdateJul 14, 2026, 07:51 AM
Valion Bio Advances Biodefense Platform, Scales Manufacturing 200-fold
AI Summary
Valion Bio, Inc. announced significant advancements across its Entolimod program, focusing on biodefense, domestic manufacturing, and oncology expansion. The company is actively engaging with U.S. government agencies and Ukraine's Ministry of Health for potential development support and strategic stockpiling of Entolimod. Valion Bio also demonstrated a 200-fold manufacturing scale-up of Entolimod through its subsidiary, Velocity Bioworks, and is preparing to expand into oncology supportive care with physician-sponsored studies.
Key Highlights
- Continued engagement with U.S. government agencies for Entolimod development support and Strategic National Stockpile opportunities.
- Discussions with Ukraine’s Ministry of Health regarding Entolimod for inclusion in national strategic reserves.
- Achieved approximately 200-fold manufacturing scale-up of Entolimod to 50-liter fermentation scale (1.3 million potential human doses).
- Advanced preparations to evaluate Entolimod in oncology supportive care, starting with neutropenia studies.
- Continued development of Entolasta, a next-generation TLR5 agonist, for oncology and immunomodulatory applications.
- Entolimod is being advanced as a medical countermeasure for Acute Radiation Syndrome (ARS) under FDA Animal Rule.
- Over $140 million has been invested in Entolimod’s development to date.
Price Impact
More from TIVC